| Drug Type Small molecule drug | 
| Synonyms 3-n-butylphthalide, Butylphthalide and Sodium Chloride, Dl-3-n-butylphthalide + [7] | 
| Target | 
| Action inhibitors | 
| Mechanism KCNK inhibitors(Potassium two pore domain channel subfamily K inhibitors), Platelet aggregation inhibitors | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date China (30 Sep 2002),  | 
| Regulation- | 
| Molecular FormulaC12H14O2 | 
| InChIKeyHJXMNVQARNZTEE-UHFFFAOYSA-N | 
| CAS Registry6066-49-5 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Butylphthalide | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Acute Ischemic Stroke | China  | 30 Sep 2002 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| ST Elevation Myocardial Infarction | Phase 3 | - | 01 Dec 2024 | |
| Dementia, Vascular | Phase 3 | China  | 29 Oct 2019 | |
| Brain Ischemia | Phase 3 | China  | 01 Jul 2011 | |
| Ischemic stroke | Phase 2 | United States  | 15 Jul 2022 | |
| Peripheral Nerve Injuries | Phase 2 | China  | 30 Mar 2022 | |
| Peripheral Nerve Injuries | Phase 2 | China  | 30 Mar 2022 | |
| Cognitive Dysfunction | Preclinical | China  | 29 May 2025 | 
| Phase 2/3 | 281 | DL-3-n-butylphthalide | zposiccpzu(roayblrryq) = qxnfrjiuis ivahwwmxjf (niozpokdnw ) View more | Positive | 01 Feb 2016 | ||
| Placebo | zposiccpzu(roayblrryq) = ystwmflsac ivahwwmxjf (niozpokdnw ) View more | 





